BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
This article was originally published in Pharmaceutical Approvals Monthly
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.
You may also be interested in...
Boehringer Ingelheim shuts down development of its female desire drug due to complications in the regulatory process.
Further safety studies of Procter & Gamble's testosterone patch Intrinsa are necessary prior to approval because of the potential for broad off-label use of the female sexual dysfunction therapy, FDA's Reproductive Health Drugs Advisory Committee said Dec. 2
Clinical studies "do not support a regulatory filing" in female sexual dysfunction because efficacy data were "inconclusive," the company says.